- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05411107
Oral Iloprost for the Prevention of Lung Cancer In Former Smokers
Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I.To determine if oral iloprost, starting at 50 ug twice daily (BID) and increased monthly to a final dose of 150 ug BID as tolerated, compared to placebo for 6 months is effective in reducing endobronchial dysplasia in former smokers who have mild or worse dysplasia on an endobronchial biopsy at baseline bronchoscopy.
SECONDARY OBJECTIVES:
I. To determine if treatment with oral iloprost compared to placebo results in a change in average dysplasia (over all sites of mild or greater dysplasia).
II. To determine safety of treatment with oral iloprost.
EXPLORATORY OBJECTIVES:
I. To determine if treatment with oral iloprost compared to placebo results in a change in response rate defined as >= 1 point reduction in maximum dysplasia.
II. To determine if the in vitro differentiation response of bronchial epithelial cell progenitors cultured at the air liquid interface is predictive of the in vivo response of dysplasia improvement (to be done only in participants recruited in Colorado).
III. To determine if treatment with oral iloprost compared to placebo results in a decrease in the volume of pure ground glass opacities (GGOs) on chest computed tomography (CT).
IV. To determine if treatment with oral iloprost compared to placebo increases peripheral lung epithelial progenitor counts, measured by organoid formation in a three dimensional culture system seeded from distal airway brushings (to be done only in participants recruited in Colorado).
V. To determine if oral iloprost reduces the incidence of lung cancer compared to placebo.
VI. To evaluate the ability of 3-dimensional morphologic analysis of expectorated sputum by LuCED compared to standard sputum cytopathology to predict endobronchial dysplasia and measure response to iloprost.
VII. To evaluate histologic response by alternative criteria.
OUTLINE: Patients are randomized in 1 of 2 arms.
ARM I: Patients receive iloprost orally (PO) BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
ARM II: Patients receive iloprost placebo PO BID for a 180 days in the absence of unacceptable toxicity. Patients undergo bronchoscopy with biopsies and brushings at day 180.
After completion of study treatment, patients are followed up for 30 days.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Rocky Mountain Regional VA Medical Center
-
Contact:
- York E. Miller
- Phone Number: 720-723-6091
- Email: york.miller@cuanschutz.edu
-
Principal Investigator:
- York E. Miller
-
Denver, Colorado, United States, 80217-3364
- University of Colorado
-
Contact:
- Nina Thomas
- Phone Number: 720-848-0123
- Email: NINA.THOMAS@CUANSCHUTZ.EDU
-
Principal Investigator:
- Nina Thomas
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
Contact:
- T. Betty Tran
- Phone Number: 312-695-9392
- Email: BETTY.TRAN@NORTHWESTERN.EDU
-
Principal Investigator:
- T. Betty Tran
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh Cancer Institute (UPCI)
-
Contact:
- David Wilson
- Phone Number: 410-687-3355
- Email: wilsondo@upmc.edu
-
Principal Investigator:
- David Wilson
-
-
Virginia
-
Richmond, Virginia, United States, 23249
- Hunter Holmes McGuire Veterans Administration Medical Center
-
Contact:
- Howard Li
- Phone Number: 4523 804-675-5000
- Email: howard.li@vcuhealth.org
-
Principal Investigator:
- Howard Li
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must be former smokers (> 12 months abstinent and confirmed by serum cotinine) with at least a 30 pack-year cigarette history who are at high risk for the development of lung cancer with at least one of the following:
- Stage I or II lung cancer survivors, surgically treated with curative intent, who have remained disease free for > 12 months. Participants may have been treated with adjuvant chemotherapy or targeted therapy [(e.g. Osimertinib for epidermal growth factor receptor (EGFR) mutation)], if appropriate, provided they are > 12 months from the last systemic adjuvant therapy dose.
- Patients with chronic obstructive pulmonary disease (COPD), defined as either airflow obstruction (forced expiratory volume in 1 second [FEV1]/forced vital capacity [FVC] < 0.70) on spirometry or emphysema (as commented on in a Radiology report) on CT scan.
- Patients who display a ground glass opacity (GGO) on CT with a largest diameter =< 10 mm and >= 4 mm on axial imaging. The GGO must either be documented to have remained the same size or slowly progressing, but not regressing, over a 6-month period of observation by serial CT scan such that further workup beyond observation is not planned. A solid component of =< 1/3 of the axial diameter may be present, providing the treating physician(s) do not plan on workup for resection within the next 6 months, taking both the character of the lesion and its rate of growth into consideration.
- Patients who have had a previous endobronchial biopsy with mild World Health Organization (WHO) score 4 or greater dysplasia
- Participants must be able to safely undergo bronchoscopy in the judgement of the investigator
- Participants must have a biopsy showing mild (grade 4 on WHO score) or greater dysplasia on the baseline bronchoscopy
- Participants must be at least 50 years old. Because no dosing or adverse event (AE) data are currently available on the use of iloprost in participants <18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Leukocytes >= 3,000/microliter
- Platelets >= 100,000/microliter
- Total bilirubin =< 2.0 mg/dl
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (ULN)
- Creatinine =< 2.0 mg/dl
- The effects of iloprost on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because prostacyclins are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- The use of any tobacco product or inhalational nicotine delivery device in the past year
- Taking any anticoagulant agent with the exception of aspirin
- Taking any antiplatelet agent
- Receiving any other investigational agents or the previous use of iloprost
- Participants may not have received radiation therapy directed to the thorax or head and neck or immunotherapy, including checkpoint inhibitors
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to iloprost
- A requirement of supplemental oxygen (O2) of >= 4 liter/minute to maintain an oxygen saturation of >= 90% at rest
- A biopsy on baseline bronchoscopy with a dysplasia score of 7 or 8 (carcinoma in situ or invasive cancer)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant women are excluded from this study because iloprost is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with iloprost breastfeeding should be discontinued if the mother is treated with iloprost.
- Due to the risk for hypotension due to vasodilator effect of iloprost, participants must not have a blood pressure < 95 mm Hg systolic
- Participants must not have a current or prior invasive cancer within the past 12 months. History of the following cancers, curatively treated by surgery or locally ablative means, at any time prior to screening is allowed: non-melanoma skin cancer and cervical carcinoma in situ. Participants with prostate cancer undergoing active surveillance are allowed.
- Participants being treated with hormonal or immune therapies, including intravesicular bacillus calmette-guerin (BCG), are excluded
- Survivors of curatively treated stage III non-small cell lung cancer (NSCLC) or any stage lung small cell carcinoma (SCLC) are excluded
- Patients with known metastatic cancer of any kind are excluded
- Participants with known underlying bleeding disorders are excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (iloprost)
Patients receive Iloprost PO BID for a 180 days in the absence of unacceptable toxicity.
Patients undergo bronchoscopy with biopsies and brushings at day 180.
|
Ancillary studies
Undergo collection of sputum sample
Other Names:
Undergo bronchial brush biopsy
Other Names:
Undergo bronchoscopy
Given PO
Other Names:
|
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO BID for a 180 days in the absence of unacceptable toxicity.
Patients undergo bronchoscopy with biopsies and brushings at day 180.
|
Ancillary studies
Given PO
Undergo collection of sputum sample
Other Names:
Undergo bronchial brush biopsy
Other Names:
Undergo bronchoscopy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in numerical grade of the worst (highest grade on the WHO scale) dysplastic lesion per subject on bronchoscopy
Time Frame: Baseline to 6 month follow up
|
Histologic response is the mean change between baseline and 6 month follow up bronchoscopy in the numerical grade of the worst (highest grade on the World Health Organization [WHO] scale) dysplastic lesion per subject.
Will be analyzed using a linear regression models with post-treatment worst grade dysplasia as the outcome variable, and treatment arm (iloprost and placebo) and baseline worst grade dysplasia as predictors.
|
Baseline to 6 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the average WHO score of all biopsy sites with a baseline score of 4 or greater
Time Frame: Up to 6 months
|
Will be assessed using bronchial biopsies according to the WHO grading system, where 1 is normal and 8 is invasive cancer.
|
Up to 6 months
|
Incidence of adverse events with oral iloprost
Time Frame: From first dose to end of study, assessed up to 6 months
|
Safety will be assessed according to a comparison of adverse events (AEs) between iloprost and placebo participants.
Descriptive statistics (frequency, percent) will be used to summarize participants' worst grade toxicity for each AE type.
AE rates will be compared between treatment arms using Fisher's exact test since AE rates are expected to be low.
|
From first dose to end of study, assessed up to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment response rate
Time Frame: Up to 6 months
|
Treatment response will be defined as >= 1 point reduction in maximum dysplasia at end of treatment, and response rates will be compared between arms using a chisquared test.
|
Up to 6 months
|
In vitro response of bronchial epithelial progenitor cells cultured at the air-liquid interface
Time Frame: Up to 6 months
|
Will compare the ability of iloprost exposure versus vehicle, to restore differentiation to ciliated and mucus secreting cells.
This will then be compared to the in vivo response of the dysplastic lesion at the same biopsy site to iloprost or placebo as a potential predictive biomarker.
This endpoint will only be assessed in biopsies from participants enrolled in Colorado.
|
Up to 6 months
|
Change in glass opacity (GGOs) volume
Time Frame: Up to 6 months
|
Changes will be summarized using descriptive statistics, and a two-sample t-test or the Wilcoxon rank-sum test will be used to compare changes between the two arms.
|
Up to 6 months
|
Organoid formation
Time Frame: Up to 6 months
|
Peripheral lung epithelial progenitor cells will be assessed for organoid formation in a three dimensional culture system before and after treatment with iloprost or placebo.The progenitor cells assay will be used to predict whether a participant will respond to iloprost (yes/no).
|
Up to 6 months
|
Morphologic analysis of expectorated sputum by LuCED
Time Frame: Up to 6 months
|
Will evaluate the ability of 3-dimensional morphologic analysis of expectorated sputum by LuCED compared to standard sputum cytopathology to predict endobronchial dysplasia and measure response to iloprost.
|
Up to 6 months
|
Histologic response by alternative criteria
Time Frame: Up to 6 months
|
Bronchoscopic biopsies of standard and visually abnormal sites will be graded on the WHO scale of dysplasia and assigned numerical scores from 1 (normal) to 8 (invasive cancer).
Each lesion will be classified as complete response, partial response, stable disease or progressive disease based on Lam et al. and each response rate will be calculated on a per-site and per-participant basis.
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: York E Miller, Northwestern University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Chronic Disease
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Lung Neoplasms
- Carcinoma
- Vasodilator Agents
- Platelet Aggregation Inhibitors
- Iloprost
Other Study ID Numbers
- NCI-2022-04698 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA060553 (U.S. NIH Grant/Contract)
- UG1CA242643 (U.S. NIH Grant/Contract)
- NCI21-08-01 (Other Identifier: Northwestern University)
- NWU21-08-01 (Other Identifier: DCP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation